entinostat has been researched along with Skin Neoplasms in 8 studies
Skin Neoplasms: Tumors or cancer of the SKIN.
| Excerpt | Relevance | Reference |
|---|---|---|
| "Cutaneous squamous cell carcinomas are a common form of highly mutated keratinocyte skin cancers that are of particular concern in immunocompromised patients." | 1.51 | Investigation into the use of histone deacetylase inhibitor MS-275 as a topical agent for the prevention and treatment of cutaneous squamous cell carcinoma in an SKH-1 hairless mouse model. ( Cole, PA; Dinkova-Kostova, AT; Eroglu, A; Fahey, JW; Holtzclaw, WD; Kalin, JH; Leigh, I; Liu, H; Proby, CM, 2019) |
| "Malignant melanoma is a highly aggressive tumor which may occur in the skin, eye, and mucous membranes." | 1.42 | The overriding of TRAIL resistance by the histone deacetylase inhibitor MS-275 involves c-myc up-regulation in cutaneous, uveal, and mucosal melanoma. ( Agliano, F; Morabito, S; Oteri, R; Teti, D; Venza, I; Venza, M; Visalli, M, 2015) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 3 (37.50) | 29.6817 |
| 2010's | 5 (62.50) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Dehmel, F | 1 |
| Ciossek, T | 1 |
| Maier, T | 1 |
| Weinbrenner, S | 1 |
| Schmidt, B | 1 |
| Zoche, M | 1 |
| Beckers, T | 1 |
| Kalin, JH | 2 |
| Wu, M | 2 |
| Gomez, AV | 1 |
| Song, Y | 1 |
| Das, J | 1 |
| Hayward, D | 1 |
| Adejola, N | 1 |
| Panova, I | 1 |
| Chung, HJ | 1 |
| Kim, E | 1 |
| Roberts, HJ | 1 |
| Roberts, JM | 1 |
| Prusevich, P | 1 |
| Jeliazkov, JR | 1 |
| Roy Burman, SS | 1 |
| Fairall, L | 1 |
| Milano, C | 1 |
| Eroglu, A | 2 |
| Proby, CM | 2 |
| Dinkova-Kostova, AT | 2 |
| Hancock, WW | 1 |
| Gray, JJ | 1 |
| Bradner, JE | 1 |
| Valente, S | 1 |
| Mai, A | 1 |
| Anders, NM | 1 |
| Rudek, MA | 1 |
| Hu, Y | 1 |
| Ryu, B | 1 |
| Schwabe, JWR | 1 |
| Mattevi, A | 1 |
| Alani, RM | 1 |
| Cole, PA | 2 |
| Liu, H | 1 |
| Holtzclaw, WD | 1 |
| Leigh, I | 1 |
| Fahey, JW | 1 |
| Kato, Y | 2 |
| Yoshino, I | 1 |
| Egusa, C | 2 |
| Maeda, T | 2 |
| Pili, R | 1 |
| Tsuboi, R | 2 |
| Venza, M | 1 |
| Visalli, M | 1 |
| Oteri, R | 1 |
| Agliano, F | 1 |
| Morabito, S | 1 |
| Teti, D | 1 |
| Venza, I | 1 |
| Hauschild, A | 1 |
| Trefzer, U | 1 |
| Garbe, C | 1 |
| Kaehler, KC | 1 |
| Ugurel, S | 1 |
| Kiecker, F | 1 |
| Eigentler, T | 1 |
| Krissel, H | 1 |
| Schott, A | 1 |
| Schadendorf, D | 1 |
| Hölsken, A | 1 |
| Eyüpoglu, IY | 1 |
| Lueders, M | 1 |
| Tränkle, C | 1 |
| Dieckmann, D | 1 |
| Buslei, R | 1 |
| Hahnen, E | 1 |
| Blümcke, I | 1 |
| Siebzehnrübl, FA | 1 |
| Trial | Phase | Enrollment | Study Type | Start Date | Status | ||
|---|---|---|---|---|---|---|---|
| A Phase I Study of Entinostat in Combination With Enzalutamide for Treatment of Patients With Castration-Resistant Prostate Cancer[NCT03829930] | Phase 1 | 6 participants (Actual) | Interventional | 2019-05-01 | Terminated (stopped due to Sponsor discontinued the drug) | ||
| [information is prepared from clinicaltrials.gov, extracted Sep-2024] | |||||||
1 trial available for entinostat and Skin Neoplasms
| Article | Year |
|---|---|
Multicenter phase II trial of the histone deacetylase inhibitor pyridylmethyl-N-{4-[(2-aminophenyl)-carbamoyl]-benzyl}-carbamate in pretreated metastatic melanoma.
Topics: Adult; Aged; Antineoplastic Agents; Benzamides; Enzyme Inhibitors; Female; Histone Deacetylase Inhib | 2008 |
7 other studies available for entinostat and Skin Neoplasms
| Article | Year |
|---|---|
Trithiocarbonates: exploration of a new head group for HDAC inhibitors.
Topics: Carbon; Carbonates; Chemistry, Pharmaceutical; Drug Design; Enzyme Inhibitors; Histone Deacetylase I | 2007 |
Targeting the CoREST complex with dual histone deacetylase and demethylase inhibitors.
Topics: Aged; Animals; Antineoplastic Agents; Benzamides; Cell Line, Tumor; Cell Proliferation; Co-Repressor | 2018 |
Investigation into the use of histone deacetylase inhibitor MS-275 as a topical agent for the prevention and treatment of cutaneous squamous cell carcinoma in an SKH-1 hairless mouse model.
Topics: Administration, Topical; Animals; Benzamides; Carcinoma, Squamous Cell; Cell Line, Tumor; Cell Proli | 2019 |
Combination of HDAC inhibitor MS-275 and IL-2 increased anti-tumor effect in a melanoma model via activated cytotoxic T cells.
Topics: Administration, Oral; Animals; Antineoplastic Combined Chemotherapy Protocols; Apoptosis; Benzamides | 2014 |
The overriding of TRAIL resistance by the histone deacetylase inhibitor MS-275 involves c-myc up-regulation in cutaneous, uveal, and mucosal melanoma.
Topics: Benzamides; CASP8 and FADD-Like Apoptosis Regulating Protein; Cell Line, Tumor; Drug Resistance, Neo | 2015 |
Combination of retinoid and histone deacetylase inhibitor produced an anti-tumor effect in cutaneous T-cell lymphoma by restoring tumor suppressor gene, retinoic acid receptorβ2, via histone acetylation.
Topics: Acetylation; Animals; Antineoplastic Combined Chemotherapy Protocols; Apoptosis; Benzamides; Benzoat | 2016 |
Ex vivo therapy of malignant melanomas transplanted into organotypic brain slice cultures using inhibitors of histone deacetylases.
Topics: Animals; Benzamides; Blood-Brain Barrier; Brain; Brain Neoplasms; Cell Line, Tumor; Cell Proliferati | 2006 |